Toll like receptor (TLR) stimulation for ocular angiogenesis and macular degeneration
US8957035B2 · kind B2 · utility
0Cited by
5References
14Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | May 15, 2007 |
| Grant date | Feb 17, 2015 |
| Priority date | — |
| Expiry date | May 6, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of stimulators of the TLR3 and TLR7 receptors, Trif or of IL-10 and IL-12 inhibits ocular angiogenesis. Furthermore, all siRNAs (both targeted and non-targeted) can inhibit ocular angiogenesis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.